- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
- Pathology1000+
- Cancer1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
- Pathology1000+
- Cancer1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- EGFR positive
- PR positive
- EGFR negative
- KRAS positive
- PD-L1 negative
- ER negative
- ALK negative
- PR negative
- BRAF positive
- CD20 positive
- BRCA1 positive
- IDH positive
- ALK positive
- BRAF negative
- BRCA2 positive
- HLA-A positive
- ROS1 negative
- HR positive
- p16 positive
- CD19 positive
- HLA positive
- TP53 positive
- MET positive
- IDH negative
- PIK3CA positive
- ROS1 positive
- dMMR positive
- MSI-H positive
- anti-dsDNA positive
- MYC positive
- ANA positive
- KRAS negative
- MET negative
- RET positive
- NF1 positive
- NRAS positive
- NTRK positive
- RAS negative
- TP53 negative
- HPV positive
- MSS positive
- PALB2 positive
- RET negative
- anti-Sm positive
- p16 negative
- BCR-ABL1 positive
- HBsAg positive
- HPV negative
- NTRK negative
- RAS positive
- RB1 positive
- pMMR positive
- ABCA4 positive
- BCL2 positive
- CCND1 positive
- CD123 positive
- CFTR positive
- HLA negative
- PTEN positive
- RB1 negative
- ctDNA positive
- dMMR negative
- APC positive
- BCL6 positive
- BRCA positive
- BRCA1 negative
- BRCA2 negative
- FGFR2 positive
- FLT3 positive
- HLA-A negative
- MDM2 positive
- MGMT negative
- MSI-H negative
- COL7A1 positive
- DMD positive
- HRAS positive
- KIT positive
- MGMT positive
- MMR negative
- NPM1 positive
- NY-ESO-1 positive
- RF positive
- TROP2 negative
- TROP2 positive
- AKT negative
- APP positive
- C5 positive
- CD30 positive
- CD5 positive
- CLDN18.2 positive
- DLL3 positive
- EBV DNA positive
- ER/PR positive
- FLT3 negative
- FMR1 positive
- FOXO1 fusion negative
- HBB positive
- HBV DNA negative
- HBsAg negative
- HR negative
- HbSS positive
- MMR positive
- NRAS negative
- NTRK1 positive
- PH positive
- PIK3CA negative
- PSEN1 positive
- PSEN2 positive
- PTCH1 positive
- PTEN negative
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- PiZZ positive
- RAF positive
- RHO positive
- SMARCA4 positive
- TET2 positive
- p53 positive
- 11q negative
- 11q positive
- AKT positive
- AKT1 positive
- ALPL positive
- APOL1 positive
- ARID1A positive
- ATM positive
- Anti-PLA2R positive
- Aβ1-42 positive
- B7-H3 positive
- BAP1 positive
- CAG repeat in HTT positive
- CCNE1 positive
- CD19 negative
- CDK4 positive
- COL1A1 positive
- COL1A2 positive
- COL3A1 positive
- DMPK positive
- EBV positive
- ER or PR positive
- Ex19del positive
- FGFR2 negative
- FGFR3 positive
- FOLR1 positive
- FOXO1 fusion positive
- FVIII positive
- GPC3 positive
- GRN positive
- HBV DNA positive
- HEXA positive
- HEXB positive
- HPV16 positive
- IGHV positive
- JAK2 positive
- KMT2A positive
- L858R positive
- LRRK2 positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSS negative
- MTAP negative
- MTAP positive
- MTOR negative
- MTOR positive
- MUC1 positive
- NF2 positive
- PDE6A positive
- PDE6B positive
- PDGFRA positive
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PMS2 positive
- PSMA positive
- RAF negative
- RB positive
- SMARCB1 negative
- SMN1 positive
- SPINK5 positive
- T790M positive
- TTR positive
- UBA1 positive
- UGT1A1 positive
- anti-AChR positive
- anti-MuSK positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Smith positive
- anti-chromatin positive
- other sickle cell syndrome variants positive
- t(11;14) positive
- t(11;14)(q13;q32) positive
- β-thalassemia positive
- 12 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adjuvant Therapy (except reconstruction)
- Alopecia from Prior Anti-Cancer Therapy
- Anemia from Prior Anti-Cancer Therapy
- Anti-Cancer Treatment
- Anti-EGFR Therapy (Cetuximab or Panitumumab)
- Anti-EGFR Therapy (Cetuximab or Panitumumab) for at least 16 weeks with CR or PR
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
8428 trials
1
2
3
…50